Cent Eur J Public Health 2011, 19(2):98-101 | DOI: 10.21101/cejph.a3634

Vaccination of Patients with Diabetes Mellitus - a Retrospective Study

Rastislav Maďar1,2, Dagmar Benešová1, Dana Brandejská1, Miriam Čermáková1, Alena Dvořáková1,3, Olga Gazárková1, Silvana Jakubalová1, Ilona Kochová1, Jana Laštovičková1,4, Dagmar Nebáznivá1,5, Marta Orolinová1, Karel Polomis1, Václav Řehka1,4, Ludmila Sattranová1, Miriam Schejbalová1,6, Alena Slámová1,6, Deanna Skalleová1, Hana Ševčíková1, Hana Tkadlecová1,7, Marta Tmějová1, Josef Trmal1,5, Dagmar Turková1
1 Vaccination centres Avenier, Czech Republic
2 Comenius University, Jessenius Faculty of Medicine, Martin, Slovakia
3 Regional Public Health Authority Jihlava, Czech Republic
4 Regional Public Health Authority Brno, Czech Republic
5 Regional Public Health Authority Ústí nad Labem, Czech Republic
6 Charles University, First Faculty of Medicine, Prague, Czech Republic
7 Regional Public Health Authority Zlín, Czech Republic

402 subjects with diabetes mellitus have been vaccinated of the total of 34,000 vaccinees immunized during the study period of 9 and half months. Altogether 229 diabetic patients (56.97%) have been vaccinated against tick-borne encephalitis (TBE) and 74 (18.4%) against viral hepatitis (41 types A+B, 30 type A, 3 type B). The average age in four most commonly administered vaccines (FSME IMMUN 0.5 ML, Twinrix Adult, Typhim Vi, and Havrix 1440) was 65, 52, 56, and 54 years, respectively. Live attenuated vaccines have been given to 6 patients with diabetes (1.49%) - 5 travellers to endemic countries received the yellow fever vaccine Stamaril (1 female, 4 male) and one male patient varicella vaccine Varilrix. Among the least common vaccines in diabetic patients were those against invasive pneumococcal and meningococcal infections. Not a single unexpected side effect has been observed following the vaccination procedure in any diabetic patient. Based on the results of this retrospective study we can conclude that vaccination in diabetic patients is free of any risk - provided that there are no other contraindications, e.g. allergy to vaccine components or severe acute febrile illness. In the case of unstable glycaemia and significantly impaired immune system due to diabetes mellitus, vaccination with live attenuated vaccines should be carefully considered and measured against the risks of exposure to each and every specific infectious agent. There is no reason to be afraid of vaccination in diabetic patients provided that general contraindications are respected. On the contrary, this risk group can benefit from vaccination more remarkably since it may have some life-saving potential.

Klíčová slova: diabetes mellitus, vaccination, killed vaccines, live attenuated vaccines, contraindications, side-effects, safety, primary care, vaccination rate, prevention

Vloženo: 10. srpen 2010; Revidováno: 2. březen 2011; Přijato: 2. březen 2011; Zveřejněno: 1. červen 2011  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Maďar R, Benešová D, Brandejská D, Čermáková M, Dvořáková A, Gazárková O, et al.. Vaccination of Patients with Diabetes Mellitus - a Retrospective Study. Cent Eur J Public Health. 2011;19(2):98-101. doi: 10.21101/cejph.a3634. PubMed PMID: 21739900.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobrazit celý článek

    Reference

    1. Maďar R, et al. How to increase vaccination rate in our population, especially in adults. Očkování a cestovní medicína. 2010;1(1):1-2. (In Czech.)
    2. Blencowe H, Lawn J, Vandelaer J, Roper M, Cousens S. Tetanus toxoid immunization to reduce mortality from neonatal tetanus. Int J Epidemiol. 2010 Apr;39 Suppl 1:i102-9. Přejít k původnímu zdroji... Přejít na PubMed...
    3. Centers for Disease Control and Prevention (CDC). Progress toward poliomyelitis eradication - Nigeria, January 2009-June 2010. MMWR Morb Mortal Wkly Rep. 2010 Jul 9;59(26):802-7.
    4. Leuridan E, Hens N, Hutse V, Ieven M, Aerts M, Van Damme P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ. 2010 May 18;340:c1626. Přejít k původnímu zdroji... Přejít na PubMed...
    5. Modlin JF. The bumpy road to polio eradication. N Engl J Med. 2010 Jun 24;362(25):2346-9. Přejít k původnímu zdroji... Přejít na PubMed...
    6. Validation of neonatal tetanus elimination in Gujarat and Himachal Pradesh, India, 2008. Wkly Epidemiol Rec. 2010 Jul 2;85(27):265-71. Přejít na PubMed...
    7. Giannattasio A, Squeglia V, Lo Vecchio A, Russo MT, Barbarino A, Carlomagno R, et al. Pneumococcal and influenza vaccination rates and their determinants in children with chronic medical conditions. Ital J Pediatr. 2010 Mar 26;36:28. Přejít k původnímu zdroji... Přejít na PubMed...
    8. Gutiérrez G, Pérez-Cuevas R, Levy S, Reyes H, Acosta B, Cantón SF, et al. Strengthening preventive care programs: a permanent challenge for healthcare systems; lessons from PREVENIMSS México. BMC Public Health. 2010 Jul 14;10:417. Přejít k původnímu zdroji... Přejít na PubMed...
    9. Richardson DK, Helderman T, Lovett P. Meningococcal epiglottitis in a diabetic adult patient: a case report. J Emerg Med. In press.
    10. Rodríguez-Rieiro C, Domínguez-Berjón MF, Esteban-Vasallo MD, Sánchez-Perruca L, Astray-Mochales J, Fornies DI, et al. Vaccination coverage against 2009 seasonal influenza in chronically ill children and adults: analysis of population registries in primary care in Madrid (Spain). Vaccine. 2010 Aug 31;28(38):6203-9. Přejít k původnímu zdroji... Přejít na PubMed...

    Zpět na obsah